secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2024-10-08T23:59:59+00:00
Accession:  0000950170-24-113526
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA reports H1 2024 net loss $10.1M, cash $12.3M; merger with Kintara on track for Q4 2024
--------------------------------------------------------------------------------

- Net loss $10.1M for six months ended June 30, 2024; prior period loss $22.1M incl $16.2M IPR&D charge.
- Cash $12.3M as of June 30, 2024, up from $3.7M at Dec 31, 2023; R&D expense $6.4M vs $4.0M YoY.
- Convertible notes payable net $16.2M; derivative liability $2.0M; accumulated deficit $98.6M.
- All-stock merger with Kintara expected to close Q4 2024; combined company to trade as HURA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024113526/0000950170-24-113526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024113526/ktra-20241007.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-113526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer